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Confidentiality and consent in medical research
Overcoming barriers to recruitment in health research
Jenny Hewison, Andy Haines
The public needs to be included in debates about what is, and isn’t, in its best interests. Until then,
ethics committees should suspend their preference for “opt-in” recruitment to research projects
The burden and expense of implementing current
research ethics and governance requirements are
beginning to be recognised.1 2 However, the ethical
requirements may also affect the quality of the primary
research. Ethics committees are now insisting that
researchers can approach only people who respond
positively to letters from their general practitioner or
hospital clinician, informing them about an opportu-
nity to take part in research—that is, people who have
opted in.3 4 However, the ethical benefits of this
approach are not proved and it can lead to low
response rates, wasted resources, and research of
limited validity.
Opting in and out
Before the changes, properly vetted and approved
researchers were allowed to contact potential partici-
pants directly after NHS staff had identified and sent
information to them about the research. The initial
letter from NHS providers stated clearly that if people
did not want to be contacted by researchers they
should let NHS staff know, so that their contact details
would not be passed to the research team—that is, they
could opt out. By contrast, many ethics committees
now require that researchers approach only people
who respond positively to a letter from their general
practitioner or hospital clinician informing them about
an opportunity to take part in research—that is, poten-
tial participants must opt in to being contacted by a
researcher.3 4 Under both systems, the researcher then
seeks informed consent for participation.
An opt-in system for approaching potential partici-
pants is claimed to benefit patients because it ensures
that only healthcare providers have access to the infor-
mation that, say, someone has diabetes unless that indi-
vidual has explicitly agreed to the information being
given to a third party. However, we believe that in most
cases the adverse effects on the conduct of methodo-
logically rigorous research more than outweigh any
putative advantages.
Firstly, scientific losses must be considered as well
as confidentiality gains. If scientific losses are real,
patients and the public need to know about them,
because they may prefer a carefully regulated opt-out
system to an opt-in system that produces evidence—
and care—of poorer quality. Such losses are likely to
vary according to the type of study but could include:
x Failure to include participants who might benefit
most from an intervention (such as those who have
more severe disease or are socioeconomically disad-
vantaged)
x Underestimation (or overestimation) of the inci-
dence or prevalence of a condition
x Biased assessment of the association between an
exposure or risk factor and a health outcome
x Failure to detect differences in quality of care and
outcome between socioeconomic or ethnic groups
x Failure to capture the full range of views and
perceptions about a health issue.
Secondly, for most patients the claimed confidenti-
ality benefits may not be real. Patients may distinguish
between different kinds of third parties and may not
consider, for example, a brief telephone call after a
letter explaining the proposed research to be an unjus-
tifiable invasion of their privacy if there seems to be a
good reason for the call and their privacy is in all other
respects protected. If, as seems likely, many people who
do not respond to a request would not object to being
approached by a researcher, an opt-in system may
deprive them of the opportunity to participate in
research or allow their records to be used for such pur-
poses. Indeed, some people might prefer an opt-out
system because of the support and reassurance that
personal contact can provide. This raises the possibility
that the advantages and disadvantages of the two
systems might be distributed differently across patient
groups. All of these arguments point in the same direc-
tion: if some kind of trade-off between confidentiality
costs and health benefits is unavoidable, the debate
about what it means to protect patients’ interests must
be public.
Evidence of compromised scientific
quality
For “catch 22” kinds of reasons, few randomised trials
have compared the numbers and characteristics of
participants recruited to research projects under opt-in
and opt-out conditions. (We know of at least one such
trial considered unacceptable by an ethics committee, I
Nazareth, personal communication). Nevertheless, two
recent studies, one a trial, have provided some relevant
information.
A randomised controlled trial comparing the two
recruitment strategies in a prognostic study of patients
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with angina concluded that the opt-in approach
“resulted in lower response rates and a biased sample.”5
The response rate to the opt-in approach was 12%
lower as judged by clinic attendances, and patients in
the opt-in arm had fewer risk factors and less
functional impairment. Once the appointment was
made attendance at the clinic was similar in the two
groups, suggesting that those recruited through the
opt-out approach were not less motivated to partici-
pate in the research.
In Scotland, a survey of 10 000 adults in which par-
ticipants had to opt in to being sent a postal (or
electronic) questionnaire about communicating their
views to the NHS achieved a response rate of 20%.4
Previous surveys in the same geographical area but
without the extra consent stage had achieved response
rates of 70-80%. There was also evidence of increased
non-response bias with the opt-in approach.
These results should be considered in the context
of extensive epidemiology and health services
research showing that apparently small procedural
changes in how research participants are recruited
can lead to scientifically important biases as well as
lower recruitment rates. Research on factors influenc-
ing the response to postal questionnaires is particu-
larly extensive,6–8 and indicates that bias and reduced
response rates under an opt-in system are not just
plausible but predictable. Until the size of such effects
is known, neither potential participants nor experts
acting on their behalf can set costs against any putative
benefits. If trials are considered unethical, we need a
meta-analysis of existing recruitment data, perhaps
supported by a consortium of research funders with
access to unpublished data from project progress
reports, etc.
Do participants object to opt-out
systems?
Catch 22 applies once again, but a recent example of a
project in which researchers were allowed to approach
patients directly is provided by the Southampton
women’s survey.9 Women were sent information and
then telephoned by researchers acting under contract
to general practitioners; more than 12 500 women
(about 75% of those contacted) agreed to join the
study. Only a small number queried the researcher’s
right to approach them, and only a handful maintained
a critical stance when the reason for the call was
explained, the researcher’s credentials were estab-
lished, and the importance of the research topic was
conveyed. This suggests that public concern about an
opt-out approach is minimal and likely to be
outweighed by the potential for harm from biased
results from opt-in approaches.
Support for the general claim that the public
considers some invasions of their privacy to be
justifiable is provided by a recent national survey that
found favourable public attitudes towards the use of
the National Cancer Registry for identifying and
contacting potential research participants.10 The right
to privacy of the minority who do not wish to be
approached is safeguarded under an opt-out system.
More debate is needed on the characteristics of
research that would, and would not, justify an opt-out
approach, but patients seem likely to view opting out as
appropriate for most projects relevant to the NHS.
Particularly sensitive topics might justify a different
strategy, but ethics committees should presume that
opting out is the best approach and opting in might
occasionally need to be used—the opposite of current
practice. The needs of people unable to opt out—for
example, because of severe mental incapacity or termi-
nal illness—have to be carefully considered, but in most
cases their doctors would be able to exclude them at
the stage of sending initial letters.
Decisions to opt in
Little is known about why many people agree to take
part in research if the researcher approaches them but
far fewer if they have to take the initiative and approach
the researcher. The opt-in figure may be argued to be a
better reflection of the numbers who actually want to
participate because researchers have no opportunity to
coerce potential participants. However, researchers are
also unable to clarify or extend the information initially
provided, which for both practical and ethical reasons is
usually kept fairly brief.
Given the important role of the initial information
sheet, do we know what information potential
participants need and wish to have in order to opt in to
research?11 And what kind of information do they
regard as coercive? Is it coercive to draw attention to a
complimentary article about the research in the local
newspaper, for example? A systematic review showed
that monetary incentives doubled the odds of
responding to postal questionnaires,6 but ethics
committees may see their inclusion as an undue
inducement. It could equally be argued, however, that it
is legitimate to compensate participants for the oppor-
tunity costs of taking part in research.
We can find out what information potential
research participants are given, and what regulatory
authorities say they should, and should not, be given.
But that is not the same as knowing what information
they would wish or need to be given. Health research
is likely to be novel for many potential participants,
and few will understand its scientific basis. Most
people may not realise the importance of a high
response rate, and so some may conclude that their
participation is not needed. Others may erroneously
assume that their response will not be useful because
they are not very articulate, because only “typical”
patients will be wanted, or because they cannot see,
read, or walk very well. Patients may also have more
hostile misconceptions. Although events at Alder Hey
did not concern legitimate research, the scandal may
nevertheless have fostered the view that research is a
morally suspect activity, conducted in pursuit of
researchers’ private interests, of poor quality, and on
topics of no importance or value to the NHS. Discus-
sion with a researcher could allay some of these
concerns.
Most participants will not want detailed explana-
tions of methodological matters, such as the problems
caused by biased samples. They are likely to prefer
reassurance that the topic is important, that impartial
and informed referees have judged the research to be
of high quality, and that their contribution is valued
and appreciated. Methodological research—for exam-
ple, on informed consent to trial participation12–15—
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supports this interpretation and also shows that
providing information may not in itself be enough to
meet the requirements of informed consent.16 A system
in which potential participants have to give their
consent to have their consent sought loses known ben-
efits with no compensating evidence that the crucial
first decision is adequately informed.
The information needs of potential participants at
the first stage of an opt-out process have not been
properly investigated either, and it is likely that
mutually beneficial changes could be made. However,
in a well regulated research environment—that is, with
further information provided as part of the full
consent process at the next stage—the consequences of
being less than adequately informed at stage one of the
opt-out arrangements are relatively minor.
Consequences of change
Certain kinds of research have suffered more than
others under the present system, but winners and
losers are determined by administrative factors not
research priorities. The least affected are projects in
which participants are recruited as they attend clinics
that have research staff in attendance. A member of
NHS staff must still identify people who are eligible
and make the initial approach, but all the patients have
to do is agree that the researcher may come over and
talk to them, which may be an agreeable diversion if
the clinic is running late. However, having a researcher
“on standby” is feasible only if there are likely to be
many eligible patients or access to research nurses (for
example) working across different projects. Except for
the most common conditions, eligible patients may be
few and far between, particularly for studies that rely
on the opportunistic recruitment of patients with spe-
cific conditions in primary care. The full impact of an
opt-in system is seen in those projects that require
records to be searched and letters to be sent:
recruitment rates are lower, more practice time must
be spent recruiting, inevitably in competition with
other priorities. The arrangement is often unsuccessful
and may lead to failure of the study.
We suggest therefore that all NHS users should
receive brief information about the potential use of
personal information for research and that a strategy
to inform individuals about how such research can
contribute to improved health should be promulgated.
The information should explain that the quality of
research depends on recruiting the right participants.
Recruitment procedures are part of the science, not an
administrative add-on, so if patients and the public
want certain kinds of research to be conducted, recruit-
ment procedures need to aim to reduce bias and
improve recruitment rates as far as possible. Since par-
ticipation in research is likely to be determined by per-
ceptions of trust and fairness, the NHS must have a
robust and forthright communication strategy to
explain why research using personal information is
needed and the importance of ensuring high
participation rates.
This series arose from discussions stimulated through participa-
tion in the MRC’s data sharing and preservation initiative, which
aims to extend new and secondary research using high value
research datasets collected with public funding for the public
good. It will lead to a web based route map through current
regulatory processes supported by guidance for good practice
when using personal data for medical research (www.mrc.ac.uk/
strategy-data_sharing_implementation.htm). We thank Peter
Dukes and Allan Sudlow for support and advice. The opinions
expressed are those of the authors.
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Summary points
Research ethics requirements are compromising
the scientific quality of health research
Opt-in systems of recruitment are likely to
increased response bias and reduce response
rates
There is no evidence that potential participants
object to a properly regulated opt-out system
The crucial first decision whether to contact a
researcher is unlikely to be adequately informed
Public debate is needed about what it means to
protect patients’ interests
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